Cargando…
B-cell activating factor targeted therapy and lupus
B-cell activating factor (BAFF), a member of the family of TNF-like cytokines, supports the survival and differentiation of B cells. The successful development of belimumab, a human antibody targeting soluble BAFF, has marked an important milestone in the development of biologic therapy for treatmen...
Autores principales: | Boneparth, Alexis, Davidson, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535720/ https://www.ncbi.nlm.nih.gov/pubmed/23281926 http://dx.doi.org/10.1186/ar3920 |
Ejemplares similares
-
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
por: Wiesik-Szewczyk, E, et al.
Publicado: (2012) -
Emerging B-Cell Therapies in Systemic Lupus Erythematosus
por: Bag-Ozbek, Ayse, et al.
Publicado: (2021) -
Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus
por: Lenert, Petar S
Publicado: (2006) -
Renal Mononuclear Phagocytes in Lupus Nephritis
por: Davidson, Anne
Publicado: (2021) -
Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)